Volume 18, Number 5—May 2012
Research
Characterization of Virulent West Nile Virus Kunjin Strain, Australia, 2011
Table 2
Virus | Monoclonal antibody, by specificity |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pan-flavivirus† |
WNV group |
WNVKUN |
Unglycosylated WNV E protein |
Glycosylated WNV E protein |
MVEV |
|||||||||
4G4, anti-NS1 | 4G2, anti-E | 2B2, anti-E | 3.91D, anti-E | 10A1, anti-E | 5H1, anti-NS5 | 10C6, anti-NS1 | ||||||||
3.101C | 17D7 | |||||||||||||
WNVNSW2011 | + | + | + | + | + | − | − | + | − | |||||
WNVKUN† | + | + | + | + | + | + | + | − | − | |||||
WNVNY99‡ | + | + | + | + | − | − | − | + | − |
*WNV, West Nile virus; KUN, Kunjin; E, envelope; MVEV, Murray Valley encephalitis virus; NS, nonstructural protein; NS, nonstructural protein; NSW, New South Wales; + positive; –, negative; NY, New York.
†Prototype WNVKUN strain MRM-61C.
‡North American WNV strain.
1These authors contributed equally to the major technical aspects of this research.
2These authors served as joint senior authors.
Page created: April 12, 2012
Page updated: April 12, 2012
Page reviewed: April 12, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.